Orexigen Therapeutics Inc OREX Financial and Strategic SWOT Analysis Review [Updated: 01022017] Prices from USD $125

22:32 EST 2 Mar 2017 | BioPortfolio Reports

Orexigen Therapeutics Inc OREX Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Orexigen Therapeutics Inc Orexigen is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. The company's lead product Contrave is an FDAapproved prescription medicine in the US, for weight loss in obese adults. Its Contrave is a naltrexone HCl or bupropion HCl extended release medication that is prescribed for obese adults or overweight adults with high cholesterol or high blood pressure. Orexigen is also approved in Europe under the brand name Mysimba. The company markets its product in Canada, Mexico and the US. The company has a subsidiary in Ireland. Orexigen is headquartered in La Jolla, California, the US.

Orexigen Therapeutics Inc Key Recent Developments

Nov 03, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016
Aug 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016
Jun 22, 2016: Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635c4
May 27, 2016: Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board
May 23, 2016: Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Orexigen Therapeutics Inc OREX Financial and Strategic SWOT Analysis Review [Updated: 01022017] Prices from USD $125


More From BioPortfolio on "Orexigen Therapeutics Inc OREX Financial and Strategic SWOT Analysis Review [Updated: 01022017] Prices from USD $125"

Quick Search


Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Prescription Drugs
A prescription drug (also prescription medication or prescription medicine) is a licensed medicine that is regulated by legislation to require a medical prescription before it can be obtained. The term is used to distinguish it from over-the-counter drug...